Alkem Laboratories - IRCTC among 8 midcap stocks hitting 52-week low; slipped up to 18% in a month
NiveshIQ
NSE: ALKEM · Pharma
Alkem Laboratories Ltd.
₹5,087.50▼ ₹50.50 (-0.98%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ALKEM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Alkem Laboratories Ltd.
Alkem Laboratories Limited is a pharmaceutical company that engages in the research, development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally, with a diverse product portfolio spanning therapeutic areas such as anti-infective, cardiology, and oncology. The company's key revenue drivers include its biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products. Recently, Alkem reported an 11% year-over-year revenue growth, driven by its strong product portfolio and strategic expansion into new markets. Despite the revenue growth, the company's net profit was impacted by tax expenses, resulting in a decline in profitability. Alkem Laboratories operates in a co
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹12,668 Cr +9.20% | ₹12,965 Cr +2.30% | ₹14,712 Cr +13.50% |
| EBITDA Margin | 17.73% | 19.38% | 24.39% |
| Net Profit | ₹1,811 Cr +79.80% | ₹2,215 Cr +22.30% | ₹2,351 Cr +6.10% |
| EPS | ₹150.19 | ₹181.12 | ₹192.51 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Markets Rally, But Alkem Laboratories Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off
Alkem Laboratories Share Price Falls to Fresh Yearly Low
🔒
+ 3 more stories about Alkem Laboratories Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹3, 740 Cr, PAT ₹521 Cr, EPS ₹43.49, EBITDA margin 24.6%. Growth context: revenue YoY +10.9%, revenue QoQ +3.8%, PAT QoQ +107.5%. Street verdict: miss, revenue surprise -1.5%, PAT surprise -7.4%.
Near-term growth is anticipated to be driven by product launches, approvals, and therapy-mix improvement, with successfu...
In FY26, the company reported revenue of ₹14, 712 Cr, PAT of ₹2, 351 Cr, an EBITDA margin of 24.4%, and EPS of ₹192.51, ...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ALKEM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ALKEM alongside your other holdings
Unlock full ALKEM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Alkem Laboratories Ltd.?
NiveshIQ detects active intelligence signals for Alkem Laboratories Ltd. (ALKEM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Alkem Laboratories Ltd.?
Alkem Laboratories Ltd. operates in the Pharma sector with a market capitalisation of ₹6,546,183.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.